AHJ:无症状冠心病植入支架预后如何?研究

2022-01-28 程震锋教授 网络

COURAGE和ISCHIMA研究提示稳定型冠心病患者与最佳药物治疗相比,血运重建能减轻症状,但不能降低死亡率。那么没有症状的稳定型缺血性心脏病 (SIHD) 患者行PCI治疗预后如何?

本文作者:湖州市中心医院  程震锋教授

COURAGE和ISCHIMA研究提示稳定型冠心病患者与最佳药物治疗相比,血运重建能减轻症状,但不能降低死亡率。那么没有症状的稳定型缺血性心脏病 (SIHD) 患者行PCI治疗预后如何?

为探讨这一问题,《美国心脏杂志》刊发了一项研究。研究在2005 年至 2018 年期间,于澳大利亚6家医院前瞻性连续纳入了接受 PCI 治疗的SIHD 患者,排除了分期接受PCI的患者。

最新研究

11730 例SIHD 患者进行了平均5 年的随访,其中 1317  (11.2%) 例是无症状的。无症状的患者年龄较大、男性更多、三支病变比例,多伴有各种合并症,包括肾功能衰竭、糖尿病和心力衰竭(均 p<0.01)。

Figure 1. Trends in rates of percutaneous coronary intervention for stable ischemic heart…

Figure 2. Kaplan meier survival curves for long-term mortality stratified by symptom…

这些患者在30天内的围手术期并发症和主要不良心血管事件的发生率明显增多,长期死亡率显著增高(27.2% vs 18.0%,p<0.001)。COX回归,临床变量校正后,无症状状态是一个长期死亡率的独立预测因子[危险比 (HR) 1.39 ,p<0.001]。

研究点评

程震锋教授

研究发现,接受 PCI 的SIHD患者中有十分之一是无症状的。

没有心绞痛或类似症状的患者围手术期并发症的发生率较高,这是短期的得不偿失。5年随访全因死亡率高约 40%,这是长期的得不偿失。

由于 SIHD 血运重建的主要目的还是缓解心绞痛,所以没有症状的患者行 PCI 需要仔细斟酌(个人觉得狭窄>90%,心功能下降的亚组患者可能获益,最好有功能学评估)。

参考文献:

Koshy AN, Dinh DT, Fulcher J, Brennan AL, Murphy AC, Duffy SJ, Reid CM, Ajani AE, Freeman M, Hiew C, Oqueli E, Farouque O, Yudi MB, Clark DJ.Long-term mortality in asymptomatic patients with stable ischemic heart disease undergoing percutaneous coronary intervention.Am Heart J. 2022 Feb;244:77-85. doi: 10.1016/j.ahj.2021.10.190

本文来源:震锋晨读,感谢授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1819972, encodeId=3d6d18199e2c3, content=<a href='/topic/show?id=4bf410018055' target=_blank style='color:#2F92EE;'>#预后如何#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100180, encryptionId=4bf410018055, topicName=预后如何)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Fri Apr 01 14:07:44 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485230, encodeId=de2714852307b, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Tue Feb 01 02:07:44 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520793, encodeId=5ecf1520e9324, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Tue Feb 01 02:07:44 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189351, encodeId=54831189351b2, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sun Jan 30 19:13:28 CST 2022, time=2022-01-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1819972, encodeId=3d6d18199e2c3, content=<a href='/topic/show?id=4bf410018055' target=_blank style='color:#2F92EE;'>#预后如何#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100180, encryptionId=4bf410018055, topicName=预后如何)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Fri Apr 01 14:07:44 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485230, encodeId=de2714852307b, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Tue Feb 01 02:07:44 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520793, encodeId=5ecf1520e9324, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Tue Feb 01 02:07:44 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189351, encodeId=54831189351b2, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sun Jan 30 19:13:28 CST 2022, time=2022-01-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1819972, encodeId=3d6d18199e2c3, content=<a href='/topic/show?id=4bf410018055' target=_blank style='color:#2F92EE;'>#预后如何#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100180, encryptionId=4bf410018055, topicName=预后如何)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Fri Apr 01 14:07:44 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485230, encodeId=de2714852307b, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Tue Feb 01 02:07:44 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520793, encodeId=5ecf1520e9324, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Tue Feb 01 02:07:44 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189351, encodeId=54831189351b2, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sun Jan 30 19:13:28 CST 2022, time=2022-01-30, status=1, ipAttribution=)]
    2022-02-01 jiyangfei
  4. [GetPortalCommentsPageByObjectIdResponse(id=1819972, encodeId=3d6d18199e2c3, content=<a href='/topic/show?id=4bf410018055' target=_blank style='color:#2F92EE;'>#预后如何#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100180, encryptionId=4bf410018055, topicName=预后如何)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Fri Apr 01 14:07:44 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485230, encodeId=de2714852307b, content=<a href='/topic/show?id=4bbe5902ed2' target=_blank style='color:#2F92EE;'>#无症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59027, encryptionId=4bbe5902ed2, topicName=无症状)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20180429/70baad2aa5a046c5aa2914d262de7d37.jpg, createdBy=bd077990475, createdName=12498da4m34(暂无昵称), createdTime=Tue Feb 01 02:07:44 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520793, encodeId=5ecf1520e9324, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Tue Feb 01 02:07:44 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1189351, encodeId=54831189351b2, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sun Jan 30 19:13:28 CST 2022, time=2022-01-30, status=1, ipAttribution=)]
    2022-01-30 医鸣惊人

    认真学习了

    0

相关资讯

Clinical Nutrition:食用橄榄油与心血管疾病和中风的风险降低有关

地中海饮食(Mediterranean diet),是泛指希腊、西班牙、法国和意大利南部等处于地中海沿岸的南欧各国以蔬菜水果、鱼类、五谷杂粮、豆类和橄榄油为主的饮食风格。

代谢综合征或胰岛素抵抗怎么就找上我!还是我胃里的“小东西”带的路?

Diabetol Metab Syndr.:幽门螺杆菌感染与代谢综合征和胰岛素抵抗风险的关系:一项最新的系统回顾和荟萃分析

这些疼痛可能是心绞痛,要当心!

研究显示约80%以上的冠心病患者在治疗后仍存在心绞痛的症状,严重影响他们的生存质量。

指南推荐《住院冠心病患者心理护理专家共识》

形成住院冠心病患者心理护理专家共识,规范对冠心病患者的心理护理。

心梗的痛,到底是种什么样的痛?

心梗的痛一定要及时鉴别!

J Clin Lipidol:在接受他汀类药物治疗的冠心病患者中,较低的LDL-C水平与较低的薄纤维帽粥样斑块发生率相关

近日,发表在《J Clin Lipidol》的一篇研究显示:在他汀类药物治疗的冠状动脉疾病(CAD)患者中,较低的LDL-C水平与罪犯斑块中的薄纤维帽粥样斑块(TCFAs)的较低发生率相关。